Clinical trial
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NCT06550895 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- September 16, 2024
- Completion date
- August 26, 2027
- Enrollment
- 11 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.